Diagnosis and Treatment of VTE in the ER
|
|
- Darrell Harrell
- 8 years ago
- Views:
Transcription
1 UHN ER Conference Nov 3, 2015 Diagnosis and Treatment of VTE in the ER Bill Geerts Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Canadian Patient Safety Institute
2 Case: Dr. Sheryl M. 28 year old EM resident Previously healthy On birth control pill x 4 mos 1 week ago (on honeymoon): ankle fracture after a fall in Hawaii no surgery but plaster cast, crutches Return to Toronto 2 days later
3 Case: Dr. Sheryl M. Oct 27 ankle fracture in Hawaii Nov 2 - sudden onset of LEFT pleuritic chest pain and shortness of breath Today - to ER with worsening of chest pain O/E: P = 95 BP = 105/78 RR = 22 (splinting) SaO2 = 93% JVP = 1 cm > sternal angle Leg looks OK above the cast Routine lab tests: normal Chest x-ray: slight blunting RIGHT CPA
4 Case: Dr. Sheryl M. What would you do now? A.Do a formal pre-test probability assessment B. Obtain a D-dimer C. Arrange a Doppler ultrasound D.Arrange a nuclear medicine lung scan E. Arrange a CTPA F. Follow the local PE investigation algorithm
5 Case: Dr. Sheryl M. What would you do now? A.Do a formal pre-test probability assessment - no B. Obtain a D-dimer - no C. Arrange a Doppler ultrasound no or? D.Arrange a nuclear medicine lung scan E. Arrange a CTPA F. Follow the local PE investigation algorithm
6 Suspected PE Assess PTP Low or Intermediate (or PE Unlikely) High Age-adjusted D-dimer Negative Positive No imaging indicated Imaging indicated
7 PE Rule-Out Criteria in Patients with Low PTP (PERC) 8 Clinical characteristics Meets criterion Age <50 0 Initial HR <100 0 Initial SvO2 >94% on room air 0 No unilateral leg swelling 0 No hemoptysis 0 No surgery, trauma <4 wks 0 No history of VTE 0 No current estrogen use 0 PTP of PE <1% if score = 0 Kline J Thromb Haemost 2004;2:124716; J Thromb Haemost 2008;6:772
8 Suspected PE Assess PTP Low Intermediate High PERC >1 D-dimer 0 Negative Positive No PE work-up indicated No imaging indicated Imaging indicated Raja Ann Intern Med 2015;163(9):701
9 4-step process starting with 64 low-value items Common, high cost, low benefit, actionable 1. Do not order CT to Dx PE without 1 st stratifying for PE (pretest prob and D-dimer for low probability). 2. Do not order lumbar spine MR if no high-risk features. 3. Do not order CT of C spine after trauma for patients who do not meet NEXUS criteria or Canadian C-Spine Rule. 4. Do not order head CT with mild head injury unless patient meets New Orleans or Canadian CT Head criteria. 5. Do not order coag tests unless patient bleeding or has suspected coagulopathy or is taking anticoagulant. Schuur JAMA Intern Med 2014;174(4):509
10 To reduce: patient radiation exposure patient contrast exposure false positive tests and detection of small filling defects of uncertain clinical significance detection of incidental findings that require further imaging, etc. the huge inter-physician variability in rates of investigation and PE ER visit time for patients costs Why should formal algorithms be used to investigate patient with suspected PE?
11
12 Case: Dr. Sheryl M. PE after ankle # Would you admit her to hospital? A. Yes B. No C. I need more information to make this decision
13 Admission Criteria for Acute VTE PE: (~50% admitted at least overnight) Hemodynamically unstable thrombolysis Requires O 2 or parenteral narcotics Very high bleeding risk Severe renal dysfunction DVT: (<5% admitted) Very high bleeding risk Severe renal dysfunction Catheter thrombolysis
14 Case: Dr. Sheryl M. PE after ankle # Which of the following management options would you start? A. IV heparin warfarin B. full-dose SC LMWH warfarin C. full-dose SC LMWH with no warfarin D. rivaroxaban 15 mg PO BID E. apixaban 10 mg PO BID F. something else...
15 VTE Treatment with rivaroxaban R enox N=8,281 EINSTEIN-DVT and EINSTEIN-PE warfarin INR 2-3 rivaroxaban 15 mg BID x 3 wks 20 mg QD Recurrent VTE Major bleeding 5-10 d 3, 6 or 12 mos usual care DVT (N=3,449) PE (N=4,832) rivaroxaban usual care rivaroxaban 3.0% 2.1% 1.8% 2.1% 1.2% 0.8% 2.2% 1.1% P=0.003 Bauersachs NEJM 2010;363:2499 EINSTEIN-PE Investigators NEJM 2012;366:1287
16 Major bleeding (%) VTE or VTErelated death (%) Apixaban for VTE Treatment (AMPLIFY) RR = 0.84 [ ] RR = 0.31 [ ] Agnelli NEJM 2013;369:799
17 Treatment of DVT/PE: 3 options 1 LMWH S/C warfarin (INR ) 5-7 d 3 mosindefinite 2 LMWH S/C? pregnancy, uncontrolled adenocarcinoma, high bleeding risk 3 rivaroxaban (Xarelto ) 15 mg PO BID x 3 wks 20 mg daily apixaban (Eliquis ) 10 mg PO BID x 1 wk 5 mg BID
18 Case: Dr. Sheryl M. PE after ankle # Which of the following management options would you start? A. IV heparin warfarin - no B. full-dose SC LMWH warfarin -? C. full-dose SC LMWH, no warfarin - OK D. rivaroxaban 15 mg PO BID E. apixaban 10 mg PO BID F. something else...
19 What are contraindications to using rivaroxaban or apixaban?
20 What are contraindications to using rivaroxaban or apixaban? 1. High bleeding risk 2. Severe renal dysfunction (CrCl <30 ml/min) 3. Severe liver dysfunction 4. Pregnancy or breast feeding 5. Massive obesity -? dose 6. Mechanical heart valve 7. Likely poor compliance 8. Some other drugs: conazoles, HIV protease inhibitors, phenytoin, carbamazepine, rifampin 9. Unable to pay
21 What are the VTE treatment doses of rivaroxaban and apixaban?
22 What are the VTE treatment dose of rivaroxaban and apixaban? rivaroxaban (Xarelto) 15 mg PO BID x 3 weeks apixaban (Eliquis) 10 mg PO BID x 1 week 20 mg once daily 5 mg BID? >6 mos 2.5 mg BID
23 Starting a FXa Inhibitor for VTE 1. Is a FXaI appropriate? NOT: high bleeding risk, severe renal/liver dysfunction, pregnancy/breast feeding, massive obesity, MHV, poor compliance, some other drugs, unable to pay? Active cancer, APLA 2. Baseline CBC, egfr, LFTs 3. Stop antiplatelet agent unless essential 4. Education esp re compliance 5. Arrange periodic follow-up
24 Case: Dr. Sheryl M. PE after ankle # Would you investigate her for DVT? A.Yes B. No
25 Case: Dr. Sheryl M. PE after ankle # Would you investigate her for occult cancer? A. Yes B. No
26 Case: Dr. Sheryl M. PE after ankle # Would you investigate her for occult cancer? A. Yes B. No What if she was 74 and had unprovoked VTE?
27 Case: Dr. Sheryl M. PE after ankle # Would you investigate her for thrombophilia? A. Yes B. No C. It depends on...
28 Case: Dr. Sheryl M. PE after ankle # Would you advise discontinuation of the birth control pill? A. Yes B. No C. It depends on...
29 If the BCP might have been a triggering factor for the VTE DVT/PE BCP Anticoagulation
30 If the BCP might have been a triggering factor for the VTE DVT/PE BCP Anticoagulation BCP Anticoagulation
31 In Dr. S.M. s case... DVT/PE BCP Anticoagulation fracture long flight PE? clotting abnormality reduced mobility?bcp
32 Case: Dr. Sheryl M. PE after ankle # Which would you say to Sheryl? A. As you know, PE is pretty serious. It s fortunate you came to the ER today because this could have killed you. B. As you know, PE can be serious but, now that it s been diagnosed and you re starting treatment, you ll be just fine.
33 Case: Dr. Sheryl M. PE after ankle # What duration of anticoagulation would you advise? A.3 months B. 6 months C. 1 year D.Until the PE has resolved E. Indefinite
34 Treatment of VTE 10% Risk of Recurrent VTE Anticoagulation unprovoked active cancer ongoing risk factor major residual DVT post-thrombotic symptoms male provoked 0 VTE Time
35 Duration of Treatment for VTE Transient, reversed risk Unprovoked Continuing risk (unresolved cancer, AT deficiency, APLA) 3 mos indefinite* indefinite*
36 Duration of Treatment for VTE Transient, reversed risk Unprovoked Continuing risk (unresolved cancer, AT deficiency, APLA) 3 mos indefinite* indefinite* *Periodic reassessment re: 1) New patient risk factors for bleeding, thrombosis 2) New knowledge 3) Patient preference
37 For most patients like you... (with unprovoked VTE) <1%/yr 5-10%/yr Anticoagulants should be continued And we will reassess this decision together periodically
38 Case: Dr. Sheryl M. PE after ankle # What duration of anticoagulation would you advise? A.3 months B. 6 months C. 1 year D.Until the PE has resolved E. Indefinite
39 Suspected VTE in ER: Summary For investigation: use an evidence-informed diagnostic algorithm with formal PTP, ageadjusted D-dimer For?DVT: Proximal Doppler U/S For?PE: CTPA, V/Q, DUS For treatment: use an evidence-informed management algorithm 1. DOAC 2. LMWH 3. LMWH warfarin Massive DVT/PE: catheter thrombolysis
Traditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationVenous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationTo define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism.
PULMONARY EMBOLISM: DIAGNOSIS AND MANAGEMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationTo provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationNational Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight
More informationPaul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationTraveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
More informationTitle Use of rivaroxaban in suspected DVT in the Emergency Department Standard Operating Procedure. Author s job title. Pharmacist.
Document Control Title Use of rivaroxaban in suspected DVT in the Emergency Department Author Pharmacist Directorate Clinical Support Services Version Date Issued Status 0.1 Oct Draft 2015 1.0 Dec Final
More informationACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationNational Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationWhat Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?
Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning A Patient s Guide to Prevention of Blood Clots During Pregnancy: Use of Blood-Thinning Drugs to Prevent Abnormal Blood
More informationInnovations in Treating VTE, Using the EDOU
Innovations in Treating VTE, Using the EDOU Disclosures No financial conflicts or disclosures Kelly Sawyer, MD, MS kelly.sawyer@beaumont.edu Observation Symposium 2013 Objectives Overview of VTE Treatment
More informationHow To Increase Warfarin
Anticoagulants for venous thromboembolic disease- Optimizing the old, ushering in the new. Daniel A. Forman, DO RPS Hematology Oncology daniel.forman@readinghealth.org 610 509 5067 cell RHS Anticoagulation
More informationChronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical
Chronic Thromboembolic Disease Diagnosis Prevention Treatment Surgical Nonsurgical Chronic Thromboembolic Disease Definition Pulmonary Hypertension due to chronic thromboembolism 6 months post acute PE:
More informationAnticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs)
Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs) Prof. P. HAINAUT Médecine Interne - Maladie Thromboembolique Cliniques Univ. Saint Luc - UCL Background Direct Oral
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationHypercoagulable States
Hypercoagulable States Daniel A. Forman, DO daniel.forman@readinghealth.org 610 509 5067 April 26, 2014 Risk Factors for Venous Thromboembolism (VTE) Hereditary thrombophilias How long to treat Newer agents
More informationPulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationHome treatment of VTE
Home treatment of VTE Prof. Adel El-Etriby Ain-Shams University Venous Thromboembolism (VTE): The DVT and PE Continuum Migration Embolus Thrombus VTE refers to a continuum of disease that begins with DVT
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationDiagnosis and Management of VTE
Diagnosis and Management of VTE Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures I have nothing to disclose
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More information10/10/13. Anil Chopra University Health Network University of Toronto
Anil Chopra University Health Network University of Toronto Participant in several advisory boards and have received unrestricted education and research grants at UHN: Leo, BI, Roche, Sanofi Aventis, Bayer,
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationPathway for the management of DVT in primary Care
Pathway for the management of DVT in primary Care Final Version: Approved by NHS DGS CCG: June 2015 This document aims to support practices in DGS CCG in the Management & Treatment of patients with suspected
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Implementation of NICE TA 261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Contents 1. Executive summary 2. Introduction
More informationConfirmed Deep Vein Thrombosis (DVT)
Confirmed Deep Vein Thrombosis (DVT) Information for patients What is deep vein thrombosis? Blood clotting provides us with essential protection against severe loss of blood from an injury to a vein or
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationResolving Controversies in Thrombosis Prevention and Treatment
Hematology Rounds Calgary February 20, 2014 Resolving Controversies in Thrombosis Prevention and Treatment Bill Geerts, MD, FRCPC Director Thromboembolism Program, Sunnybrook HSC Professor of Medicine,
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationGuidelines for diagnosis and management of acute pulmonary embolism
Guidelines for diagnosis and management of acute pulmonary embolism By Dr. Ahmed Zaghloul M.D. Anesthesia & Critical Care 2014 Predisposing factors for VTE Predisposing factor Strong predisposing factors
More informationThe Prescribing pathway consists of a number of parts:
NHS EAST LANCASHIRE CCG & NHS BLACKBURN WITH DARWEN CCG DVT Primary Care Prescribing Pathway www.elmmb.nhs.uk Introduction www.elmmb.nhs.uk Version 1.2/January 2013 Introduction Blackburn with Darwen and
More informationUse of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps
Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps Cheryl Ea, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)
ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 6, Issue 1 Newsletter Date: January 2014 APSR EDUCATION PUBLICATION Inside this issue: Venous thromboembolism Pulmonary embolism and deep vein thrombosis. 2 Outpatient versus
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013 General Principles: There is compelling data in the medical literature to support
More informationA PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT
A PATIENT S GUIDE TO PULMONARY EMBOLISM TREATMENT This medicine is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationImplementation of NICE TAs 261 and 287
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group Northampton General Hospital NHS Trust Northamptonshire Healthcare Foundation Trust Implementation
More informationInformation for you Treatment of venous thrombosis in pregnancy and after birth. What are the symptoms of a DVT during pregnancy?
Information for you Treatment of venous thrombosis in pregnancy and after birth Published in September 2011 What is venous thrombosis? Thrombosis is a blood clot in a blood vessel (a vein or an artery).
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationHaematology for GP s Part 2. Anticoagulation in DVT and PE VTE. Introduction. DVT Principles of diagnosis. VTE in Bradford
Haematology for GP s Part 2 Anticoagulation in DVT and PE Introduction NICE guidelines DVT and PE diagnosis and treatment Warfarin New anticoagulants Cases VTE VTE is an important cause of morbidity and
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationThrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
More informationUncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser
Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationEINSTEIN DVT/PE IMPORTANT SAFETY INFORMATION
EINSTEIN DVT/PE % INDICATIONS is indicated for the treatment of deep vein thrombosis (DVT). is indicated for the treatment of pulmonary embolism (PE). is indicated for the reduction in the risk of recurrence
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationHigh Risk Emergency Medicine
High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine No relevant financial relationships to disclose
More informationNew Oral Anticoagulants (NOACs)
New Oral Anticoagulants (NOACs) Dabigatran (Pradaxa) Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Janice Lawson, MD Tallahassee Memorial Hospital Cancer and Hematology Specialists Disclosure
More informationVolume 7; Number 19 November 2013
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationAnticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice. B. Gail Macik, MD Professor of Medicine & Pathology
Anticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice Virginia Association of Hematology & Oncology Spring Meeting April 18, 2015 B. Gail Macik, MD Professor of Medicine
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationTRANSITIONS OF CARE FOR PATIENTS ON ANTICOAGULATION THERAPY
TRANSITIONS OF CARE FOR PATIENTS ON ANTICOAGULATION THERAPY Lynn Oertel, MS, ANP, CACP Clinical Nurse Specialist, MGH, Boston, MA April 2 2014 24 th Annual Conference on Cardiovascular Nursing AHA Presenter
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationCHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4
LAMC Department of Pharmacy Services: ANTICOAGULATION: Surgical Intervention Table 1: Classification of Surgical interventions according to bleeding risk t required to discontinue anticoagulation Dental
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More information6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
More informationHemostasis and Thrombosis Update for Primary Care Providers. Primary Care Medicine: Principles and Practice. Topic Outline
Hemostasis and Thrombosis Update for Primary Care Providers Primary Care Medicine: Principles and Practice Topic Outline Non-Vitamin K antagonist Oral Anti-Coagulants NOACs Background on these agents Use
More informationFULL REVIEW. PBS listing. Rivaroxaban (Xarelto) NPS RADAR AUGUST 2013 KEY POINTS
1 FULL REVIEW for treatment of deep vein thrombosis and pulmonary embolism, and for prevention of venous thromboembolism recurrence (riv-ah-rocks-ah-ban) An alternative to parenteral anticoagulation with
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationRivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists
Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers
More informationNovel Anticoagulants
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
More informationTimeline: FDA approval of NOACs. FDA-approved oral anticoagulants. FDA-approved oral anticoagulants. Stroke risk reductions: afib RCTs 4/8/2016
Christina York, PharmD, BCPS Pharmacology Conference April 2016 Objectives Compare current FDA-approved oral anticoagulants Understand practical issues that arise with novel oral anticoagulants Consider
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More information